ΕΛ.Ι.Ε.Κ.

Διεθνείς Συνεργασίες 2014-2017

GENOME-WIDE ASSOCIATION STUDY IDENTIFIES 25 KNOWN BREAST CANCER SUSCEPTIBILITY LOCI AT RISK FACTORS FOR TRIPLE-NEGATIVE BREAST CANCER 

KS. Purrington , S. Slager, D. Eccles, D. Yannoukakos, PA. Fasching, ... D. Yannoukakos, I. Konstantopoulou, F. Fostira, A. Vratimos,P. Apostolou, I. Konstanta, V. Kotoula, S. Lakis, MA. Dimopoulos, D. Skarlos, D. Pectasides, G. Fountzilas

Carcinogenesis. 2014 May;35(5):1012-9. doi: 10.1093/carcin/bgt404.

IN SITU QUANTITATIVE MEASUREMENT OF HER2mRNA PREDICTS BENEFIT FROM TRASTUZUMAB-CONTAINING CHEMOTHERAPY IN A COHORT OF METASTATIC BREAST CANCER PATIENTS 

M. Vassilakopoulou, T. Togun, U. Dafni, H. Cheng, J. Bordeaux, VM. Neumeister, M. Bobos, G. Pentheroudakis, DV. Skarlos, D. Pectasides, V. Kotoula, G. Fountzilas,DL. Rimm, A. Psyrri

PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131.

GENETIC VARIATION IN MITOTIC REGULATORY PATHWAY GENES IS ASSOCIATED WITH BREAST TUMOR GRADE

K.S. Purrington…. D. Yannoukakos…. F. Fostira, G. Fountzilas, I. Konstantopoulou….

Hum Mol Genet. 2014 Nov 15;23(22):6034-46. doi: 10.1093/hmg/ddu300.

INHERITED MUTATIONS IN 17 BREAST CANCER SUSCEPTIBILITY GENES AMONG A LARGE TRIPLE-NEGATIVE BREAST CANCER COHORT UNSELECTED FOR FAMILY HISTORY OF BREAST CANCER

F.J. Couch, S.N. Hart, …….I. Konstantopoulou, F. Fostira, A. Vratimos, G. Fountzilas, …..D. Yannoukakos, S.L. Slager, C.M. Vachon, D.M. Eccles, and P.A. Fasching

Journal of Clinical Oncology, 33(4), 304-311, 2015

MEASUREMENT OF DOMAIN-SPECIFIC HER2 (ERBB2) EXPRESSION MAY CLASSIFY BENEFIT FROM TRASTUZUMAB IN BREAST CANCER

D.E Carvajal-Hausdorf, K.A Schalper, Pusztai L, A. Psyrri, K.T Kalogeras, V. Kotoula, G. Fountzilas, D.L Rimm

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136.

FCGR POLYMORPHISMS AND CETUXIMAB EFFICACY IN CHEMO-REFRACTORY METASTATIC COLORECTAL CANCER: AN INTERNATIONAL CONSORTIUM STUDY

R. Geva, L. Vecchione, K.T. Kalogeras, B. Vittrup Jensen, H.J Lenz , T. Yoshino, D. Paez, C. Montagut, J. Souglakos, F. Cappuzzo, A. Cervantes, M. Frattini, G. Fountzilas, J.S. Johansen, E.V Høgdall , W. Zhang, D. Yang, K. Yamazaki, T. Nishina, D. Papamichael, B. Vincenzi, T. Macarulla, F. Loupakis , J. De Schutter, K.L Garm Spindler, P. Pfeiffer, F. Ciardiello, H. Piessevaux, S. Tejpar

Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234.

GENES ASSOCIATED WITH HISTOPATHOLOGIC FEATURES OF TRIPLE NEGATIVE BREAST TUMORS PREDICT MOLECULAR SUBTYPES

Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rüdiger T, Heikkilä P, Blomqvist C, Cross SS, Southey MC, Olson JE, Gilbert J, Deming-Halverson S, Kosma VM, Clarke C, Scott R, Jones JL, Zheng W, Mannermaa A; Jane Carpenter for ABCTC Investigators, Eccles DM, Vachon CM, Couch FJ.

Breast Cancer Res Treat. 2016 May;157(1):117-31. doi: 10.1007/s10549-016-3775-2. Epub 2016 Apr 15.

MALE BREAST CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS: PATHOLOGY DATA FROM THE CONSORTIUM OF INVESTIGATORS OF MODIFIERS OF BRCA1/2. 

Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL,….Garber J, Fostira F, Fountzilas G, Chenevix-Trench G, Antoniou AC, Ottini L.

Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.

EVALUATION OF PD-L1 EXPRESSION AND ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTES IN LARYNGEAL SQUAMOUS CELL CARCINOMA

Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543.

EVALUATION OF CPG ISLAND METHYLATOR PHENOTYPE AS A BIOMARKER IN COLORECTAL CANCER TREATED WITH ADJUVANT OXALIPLATIN 

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2016 Jun;15(2):164-9. doi: 10.1016/j.clcc.2015.10.005.

EVALUATION OF PD-L1 EXPRESSION AND ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTES IN LARYNGEAL SQUAMOUS CELL CARCINOMA

Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A.

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543

ASSOCIATION OF BREAST CANCER RISK IN BRCA1 AND BRCA2 MUTATION CARRIERS WITH GENETIC VARIANTS SHOWING DIFFERENTIAL ALLELIC EXPRESSION: IDENTIFICATION OF A MODIFIER OF BREAST CANCER RISK AT LOCUS 11Q22.3.

Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caligo MA, Chiquette J, Chung WK, Claes KB, Daly MB, Damiola F, Davidson R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B; EMBRACE., Engel C, Gareth Evans D, Feliubadalo L, Foretova L, Fostira F, Foulkes WD, Fountzilas G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther SA; GEMO Study Collaborators., Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TV, Hart S, Hays JL; HEBON., Hogervorst FB, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Just W, Kaczmarek K, Karlan BY; KConFab Investigators., Kets CM, Kirk J, Kriege M, Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren A, Loman N, Loud JT, Manoukian S, Mariani M, Mazoyer S, McGuffog L, Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nussbaum RL, Olah E, Olopade OI, Ong KR, Oosterwijk JC, Osorio A, Papi L, Park SK, Pedersen IS, Peissel B, Segura PP, Peterlongo P, Phelan CM, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Richardson A, Robson M, Rodriguez GC, Rookus MA, Schmutzler RK, Sevenet N, Shah PD, Singer CF, Slavin TP, Snape K, Sokolowska J, Sønderstrup IM, Southey M, Spurdle AB, Stadler Z, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Tan Y, Tea MK, Teixeira MR, Teulé A, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van den Ouweland AM, van der Luijt RB, van Engelen K, van Rensburg EJ, Varon-Mateeva R, Wappenschmidt B, Wijnen JT, Rebbeck T, Chenevix-Trench G, Offit K, Couch FJ, Nord S, Easton DF, Antoniou AC, Simard J.

Breast Cancer Res Treat. 2017 Jan;161(1):117-134. doi: 10.1007/s10549-016-4018-2. Epub 2016 Oct 28.

IDENTIFICATION OF 12 NEW SUSCEPTIBILITY LOCI FOR DIFFERENT HISTOTYPES OF EPITHELIAL OVARIAN CANCER.

Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826.

THE CPG ISLAND METHYLATOR PHENOTYPE IS CONCORDANT BETWEEN PRIMARY COLORECTAL CARCINOMA AND MATCHED DISTANT METASTASES.

Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM.

Clin Epigenetics. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1.